Interleukin-2 initiates metabolic responses associated with critical illness in humans (Q40783141)

23 September 2017

title

Interleukin-2 initiates metabolic responses associated with critical illness in humans (English)

1 reference

23 September 2017

0 references

H R Michie

1

1 reference

23 September 2017

T J Eberlein

2

1 reference

23 September 2017

D R Spriggs

3

1 reference

23 September 2017

K R Manogue

4

1 reference

23 September 2017

A Cerami

5

1 reference

23 September 2017

D W Wilmore

6

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 October 1988

1 reference

23 September 2017

1 reference

23 September 2017

volume

208

1 reference

23 September 2017

issue

4

1 reference

23 September 2017

page(s)

493-503

1 reference

Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta

23 September 2017

cites work

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

The induction of interleukin-1 in humans and its metabolic effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Both inflammatory and endocrine mediators stimulate host responses to sepsis

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Effects of infection on oxygen consumption and core temperature in experimental thermal injury

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

https://pubmed.ncbi.nlm.nih.gov/2845872

1 reference

12 December 2020

Effects of gamma-interferon on the endocrine system: results from a phase I study

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Effects of indomethacin on endocrine responses and nitrogen loss after surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Ibuprofen-associated renal dysfunction. Pathophysiologic mechanisms of acute renal failure, hyperkalemia, tubular necrosis, and proteinuria

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Inhibition of cyclo-oxygenase attenuates the metabolic response to endotoxin in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Detection of circulating tumor necrosis factor after endotoxin administration.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Recombinant interleukin-2 (rIL-2) improves immune response and host resistance to septic challenge in thermally injured mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

https://pubmed.ncbi.nlm.nih.gov/2845872

1 reference

12 December 2020

Effect of ambient temperature on heat production and heat loss in burn patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Alterations in hypothalamic function following thermal injury

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Combined hormonal infusion simulates the metabolic response to injury

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Mechanism of prevention of postburn hypermetabolism and catabolism by early enteral feeding

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Mechanisms of fever induced by recombinant human interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Use of monoclonal antibodies as sensitive and specific probes for biologically active human gamma-interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2845872

12 December 2020

10.1097/00000658-198810000-00011

Identifiers

DOI

1 reference

23 September 2017

0 references

1 reference